Literature DB >> 30319982

Proposal of Primary Endpoints for TACE Combination Trials with Systemic Therapy: Lessons Learned from 5 Negative Trials and the Positive TACTICS Trial.

Masatoshi Kudo1.   

Abstract

Entities:  

Year:  2018        PMID： 30319982      PMCID： PMC6167729          DOI： 10.1159/000492535

Source DB:  PubMed          Journal:  Liver Cancer        ISSN： 1664-5553            Impact factor:   11.740


× No keyword cloud information.
  21 in total

1.  Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.

Authors:  Jordi Bruix; Jean-Luc Raoul; Morris Sherman; Vincenzo Mazzaferro; Luigi Bolondi; Antonio Craxi; Peter R Galle; Armando Santoro; Michel Beaugrand; Angelo Sangiovanni; Camillo Porta; Guido Gerken; Jorge A Marrero; Andrea Nadel; Michael Shan; Marius Moscovici; Dimitris Voliotis; Josep M Llovet
Journal:  J Hepatol       Date:  2012-06-19       Impact factor: 25.083

Review 2.  Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update.

Authors:  Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Masumi Kadoya; Takuji Okusaka; Shiro Miyayama; Koichiro Yamakado; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami
Journal:  Oncology       Date:  2014-11-22       Impact factor: 2.935

3.  Molecular Targeted Agents for Hepatocellular Carcinoma: Current Status and Future Perspectives.

Authors:  M Kudo
Journal:  Liver Cancer       Date:  2016-12-15       Impact factor: 11.740

4.  The Overall Survival of Patients with Hepatocellular Carcinoma Correlates with the Newly Defined Time to Progression after Transarterial Chemoembolization.

Authors:  Tadaaki Arizumi; Kazuomi Ueshima; Mina Iwanishi; Tomohiro Minami; Hirokazu Chishina; Masashi Kono; Masahiro Takita; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Hiroshi Ida; Yoriaki Komeda; Mamoru Takenaka; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2017-05-09       Impact factor: 11.740

Review 5.  Transarterial Chemoembolization in Combination with a Molecular Targeted Agent: Lessons Learned from Negative Trials (Post-TACE, BRISK-TA, SPACE, ORIENTAL, and TACE-2).

Authors:  Masatoshi Kudo; Tadaaki Arizumi
Journal:  Oncology       Date:  2017-12-20       Impact factor: 2.935

6.  Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.

Authors:  Masatoshi Kudo; Kazuho Imanaka; Nobuyuki Chida; Kohei Nakachi; Won-Young Tak; Tadatoshi Takayama; Jung-Hwan Yoon; Takeshi Hori; Hiromitsu Kumada; Norio Hayashi; Shuichi Kaneko; Hirohito Tsubouchi; Dong Jin Suh; Junji Furuse; Takuji Okusaka; Katsuaki Tanaka; Osamu Matsui; Michihiko Wada; Iku Yamaguchi; Toshio Ohya; Gerold Meinhardt; Kiwamu Okita
Journal:  Eur J Cancer       Date:  2011-09       Impact factor: 9.162

7.  Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.

Authors:  Tim Meyer; Richard Fox; Yuk Ting Ma; Paul J Ross; Martin W James; Richard Sturgess; Clive Stubbs; Deborah D Stocken; Lucy Wall; Anthony Watkinson; Nigel Hacking; T R Jeffry Evans; Peter Collins; Richard A Hubner; David Cunningham; John Neil Primrose; Philip J Johnson; Daniel H Palmer
Journal:  Lancet Gastroenterol Hepatol       Date:  2017-06-23

8.  Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level.

Authors:  Xin Li; Gan-Sheng Feng; Chuan-Sheng Zheng; Chen-Kai Zhuo; Xi Liu
Journal:  World J Gastroenterol       Date:  2004-10-01       Impact factor: 5.742

9.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

10.  Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.

Authors:  Masatoshi Kudo; Ann-Lii Cheng; Joong-Won Park; Jae Hyung Park; Po-Chin Liang; Hisashi Hidaka; Namiki Izumi; Jeong Heo; Youn Jae Lee; I-Shyan Sheen; Chang-Fang Chiu; Hitoshi Arioka; Satoshi Morita; Yasuaki Arai
Journal:  Lancet Gastroenterol Hepatol       Date:  2017-10-04
View more
  8 in total

Review 1.  [Locoregional and local ablative treatment options for liver tumors].

Authors:  J B Hinrichs; F K Wacker
Journal:  Internist (Berl)       Date:  2020-02       Impact factor: 0.743

2.  Deep Learning Predicts Overall Survival of Patients With Unresectable Hepatocellular Carcinoma Treated by Transarterial Chemoembolization Plus Sorafenib.

Authors:  Lei Zhang; Wei Xia; Zhi-Ping Yan; Jun-Hui Sun; Bin-Yan Zhong; Zhong-Heng Hou; Min-Jie Yang; Guan-Hui Zhou; Wan-Sheng Wang; Xing-Yu Zhao; Jun-Ming Jian; Peng Huang; Rui Zhang; Shen Zhang; Jia-Yi Zhang; Zhi Li; Xiao-Li Zhu; Xin Gao; Cai-Fang Ni
Journal:  Front Oncol       Date:  2020-09-30       Impact factor: 6.244

3.  Prognosis Nomogram for Hepatocellular Carcinoma Patients with Portal Vein Invasion Undergoing Transarterial Chemoembolization Plus Sorafenib Treatment: A Retrospective Multicentre Study.

Authors:  Lei Zhang; Jun-Hui Sun; Zhong-Heng Hou; Bin-Yan Zhong; Zhi-Ping Yan; Cai-Fang Ni; Min-Jie Yang; Guan-Hui Zhou; Wan-Sheng Wang; Peng Huang; Shen Zhang; Zhi Li; Xiao-Li Zhu
Journal:  Cardiovasc Intervent Radiol       Date:  2020-09-23       Impact factor: 2.740

4.  Transarterial Chemoembolization (TACE) Combined with Sorafenib versus TACE Alone for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Study.

Authors:  Baosheng Ren; Wansheng Wang; Jian Shen; Wanci Li; Caifang Ni; Xiaoli Zhu
Journal:  J Cancer       Date:  2019-01-29       Impact factor: 4.207

5.  Dynamic Nomogram for Predicting Macrovascular Invasion of Patients with Unresectable Hepatocellular Carcinoma after Transarterial Chemoembolization.

Authors:  Huiwen Yan; Xinhui Wang; Dongdong Zhou; Peng Wang; Zhiyun Yang
Journal:  J Cancer       Date:  2022-03-28       Impact factor: 4.207

6.  Comparison of the Efficacy and Safety of Transarterial Chemoembolization with or without Lenvatinib for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score-Matched Analysis.

Authors:  Yu-Xing Chen; Jin-Xing Zhang; Chun-Gao Zhou; Jin Liu; Sheng Liu; Hai-Bin Shi; Qing-Quan Zu
Journal:  J Hepatocell Carcinoma       Date:  2022-08-01

7.  Evolution of Transarterial Chemoembolization for the Treatment of Liver Cancer.

Authors:  Kyung Won Kim; Annick D Van den Abbeele
Journal:  Radiology       Date:  2019-10-15       Impact factor: 29.146

8.  Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib.

Authors:  Shintaro Azuma; Haruki Uojima; Makoto Chuma; Xue Shao; Hisashi Hidaka; Takahide Nakazawa; Masaaki Kondo; Kazushi Numata; Shogo Iwabuchi; Makoto Kako; Shin Maeda; Wasaburo Koizumi; Koichiro Atsuda
Journal:  Sci Rep       Date:  2020-10-13       Impact factor: 4.379
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.